To effectively manage increased patient volumes and financial demands, healthcare organizations are adopting solutions for electronic patient records and systems that allow them to share patient information in real-time. This segment of e-health is growing, and the growth is expected to accelerate in the coming years. Ortivus is well-positioned to capitalize on this development.
Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.
| Stock Symbol | ISIN | Shares outstanding | Votes/share | |
|---|---|---|---|---|
| Class A | ORTI A | SE0000188930 | 1,662,682 | 10 |
| Class B | ORTI B | SE0000123085 | 42,644,786 | 1 |
The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,807,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.
Ortivus A
Ortivus B
Subscribe to Financial Information
- Ortivus protokoll årsstämma 2019
- Ortivus protokoll årsstämma 2019 bilagor 2-4
- Ersättning till ledande befattningshavare revisorns yttrande
- Fullmaktsblankett
- Kallelse till årsstämma i Ortivus AB
- Ortivus styrelsen redovisning av resultatet av ersättningskommitten
- Ortivus valberedningens arbete 2019
- Ortivus valberedningens motiverade yttrande 2019
- Styrelsens förslag till riktlinjer för ersättning till ledande befattningshavare
ORTIVUS SIGN CONTRACT WITH ST ENGINEERING’S ELECTRONICS SECTOR TO ADVANCE PRE-HOSPITAL SOFTWARE IN SINGAPORE
September 30, 2019
Ortivus continues to expand internationally and deliver value to the medical records system in Singapore
Read moreORTIVUS HAS BEEN SELECTED AS PREFERRED BIDDER FOR PREHOSPITAL CARE BY THE SOUTH WESTERN AMBULANCE SERVICE TRUST (SWAST)
September 24, 2019
Ortivus has been selected as the preferred bidder to deliver its prehospital MobiMed electronic patient
Read moreOrtivus agreement with Northern Ireland Ambulance Service HSC Trust on ambulance records now signed
August 12, 2019
Ortivus, as previously announced (March 22nd, 2019), has been awarded a contract for the delivery
Read moreFinansinspektionen: Flaggningsmeddelande i Ortivus Aktiebolag
June 18, 2019
Flaggningsmeddelande i Ortivus Aktiebolag Anmälan om förvärv eller överlåtelse av finansiella instrument. Emittent 556259-1205 Ortivus
Read moreReidar Gårdebäck utsedd till ny vd för Ortivus
June 13, 2019
Styrelsen för Ortivus AB har beslutat utse Reidar Gårdebäck till ny verkställande direktör för Ortivus
Read moreOrtivus AB (publ) (“Ortivus”) genomför en riktad nyemission- tillförs 15 MSEK
May 17, 2019
Styrelsen för Ortivus AB (publ) har med stöd av bemyndigande från årsstämman 2019 beslutat om
Read moreKommuniké från Ortivus AB (publ) årsstämma den 6 maj 2019
May 6, 2019
Aktieägarna i Ortivus AB (publ) höll årsstämma måndagen den 6 maj 2019 i Danderyd. Här
Read moreDelårsrapport för perioden januari – mars 2019 Ortivus AB (publ)
May 3, 2019
Ortivus vinner ny kund i Nordirland värt 32 MSEK JANUARI – MARS 2019 Nettoomsättningen uppgick
Read moreThe board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations.
(Documents below are in Swedish only)
The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations.